Kathryn Parsley
Kathryn Parsley is Senior Director, Regulatory Affairs, Gyroscope Therapeutics, A Novartis Company, UK.
JournalEvolution of GMO requirements for innovative investigational medicinal products upon transition to the EU CTR
The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs).